Rilutek
E561109
Rilutek is a brand-name medication containing riluzole, used to slow the progression of amyotrophic lateral sclerosis (ALS).
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
brand-name medication
ⓘ
pharmaceutical drug ⓘ riluzole-containing product ⓘ |
| actsOn | glutamatergic neurotransmission ⓘ |
| administrationSchedule | twice daily dosing is typical ⓘ |
| advice |
avoid high-fat meals close to dosing
ⓘ
take on an empty stomach ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedFor | treatment of ALS ⓘ |
| belongsTo | ALS disease-modifying therapies ⓘ |
| commonAdverseEffect |
dizziness
ⓘ
elevated liver enzymes ⓘ nausea ⓘ weakness ⓘ |
| contains | riluzole 50 mg per tablet (typical strength) ⓘ |
| contraindication |
history of severe hypersensitivity to riluzole
ⓘ
severe hepatic impairment ⓘ |
| developedFor | modifying disease course in ALS ⓘ |
| doesNot | cure ALS ⓘ |
| dosageForm | oral tablet ⓘ |
| drugInteraction |
CYP1A2 inducers may decrease riluzole exposure
ⓘ
CYP1A2 inhibitors may increase riluzole exposure ⓘ |
| effect |
delays need for tracheostomy in ALS patients
ⓘ
modestly prolongs survival in ALS ⓘ |
| eliminationRoute | renal excretion of metabolites ⓘ |
| hasActiveIngredient | riluzole NERFINISHED ⓘ |
| hasATCCode | N07XX02 ⓘ |
| indicatedFor |
ALS
ⓘ
amyotrophic lateral sclerosis ⓘ |
| mechanismOfAction |
inactivates voltage-dependent sodium channels in CNS
ⓘ
inhibits glutamate release ⓘ interferes with intracellular events following excitatory amino acid receptor binding ⓘ |
| metabolism | extensively metabolized in the liver ⓘ |
| metabolizingEnzyme | CYP1A2 ⓘ |
| notIndicatedFor | pediatric patients ⓘ |
| pharmacologicalClass | glutamate release inhibitor ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| regulatoryStatus | prescription-only medicine ⓘ |
| requiresMonitoring | liver function tests ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect | hepatotoxicity ⓘ |
| storageCondition | store at controlled room temperature ⓘ |
| targetPopulation | adults with ALS ⓘ |
| therapeuticUse | slowing progression of ALS ⓘ |
| warning |
discontinue if significant liver enzyme elevation occurs
ⓘ
use with caution in patients with liver disease ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Riluzole